Patents Assigned to Merck
  • LC medium
    Patent number: 11739267
    Abstract: LC media and LC displays containing an LC medium with positive dielectric anisotropy, which contains one or more compounds of formula I in a concentration of >0 and ?10% and displays addressed by an active matrix and in particular displays of the IPS, PS-IPS, FFS, PS-FFS, HB-FFS, U-IPS, TN, PS-TN, STN or TN-TFT mode.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: August 29, 2023
    Assignee: MERCK PATENT GMBH
    Inventors: Yeon-Jeong Han, Dong-Hyun Kim, Heui-Seok Jin, Chang-Suk Choi
  • Method to increase cellular availability of calcium in skin cells and mixtures
    Patent number: 11737997
    Abstract: The present invention relates to mixtures of serine or threonine together with at least one further amino acid or amino acid derivative and with at least one calcium salt or its hydrate and methods including this mixture including specific mixtures of such components and a formulations consisting of the mixture and a solvent.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: August 29, 2023
    Assignee: Merck Patent GmbH
    Inventors: Alexander Paul Schiller, Lisa Eckelhoefer, Julia Bleifuss, Andrew Philip Salazar, Joerg von Hagen
  • Polymerisable compounds and the use thereof in liquid-crystal displays
    Patent number: 11739266
    Abstract: The present invention relates to polymerisable compounds, to processes and intermediates for the preparation thereof, to liquid-crystal (LC) media comprising them, and to the use of the polymerisable compounds and LC media for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the polymer sustained alignment (PS, PSA) and self-aligning (SA) type.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: August 29, 2023
    Assignee: MERCK PATENT GMBH
    Inventors: Qiong Tong, Rocco Fortte, Helmut Haensel, Edward Plummer, Timo Uebel, Oliver Heppert
  • Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
    Patent number: 11739143
    Abstract: The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: August 29, 2023
    Assignees: TEIJIN PHARMA LIMITED, MERCK SHARP & DOHME LLC
    Inventors: Hiroshi Eguchi, Takashi Murakami, Naoko Namiki, Akira Tanokura, Jeanne E. Baker, Sophie Parmentier Batteur, Angela Marie Jablonski, Daniel Stephen Malashock, Carl Mieczkowski, Gopalan (Raghu) Raghunathan
  • Aromatic isothiocyanates
    Patent number: 11739265
    Abstract: The present invention relates to aromatic isothiocyanates of formula U as defined in claim 1, to liquid-crystalline media comprising one or more compounds of formula U and to high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas, e.g. phased array antennas.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: August 29, 2023
    Assignee: Merck Patent GmbH
    Inventors: Constanze Brocke, Dmitry Ushakov, Katharina Linke, Dagmar Klass, Carsten Fritzsch
  • Process of preparing colored solar cells
    Patent number: 11742445
    Abstract: A process for the preparation of colored solar cells or colored solar cell modules containing a colored polymer film with oriented effect pigments, and colored solar cells or colored solar cell modules prepared by this process.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: August 29, 2023
    Assignee: MERCK PATENT GMBH
    Inventors: Marc Hunger, Sebastian Barth, Laurent Deloux
  • Oxazolidinones as TarO inhibitors
    Patent number: 11738010
    Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.
    Type: Grant
    Filed: July 26, 2021
    Date of Patent: August 29, 2023
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: John P. Caldwell, Reynalda De Jesus, Fa-Xiang Ding, Charles J. Gill, Ginny Dai Ho, Sookhee N. Ha, Sandra J. Koseoglu, Marc A. Labroli, Sang Ho Lee, Christina Madsen-Duggan, Mihir Mandal, Terry Roemer, Jing Su, Christopher Michael Tan, Zheng Tan, Haifeng Tang, Hao Wang, Christine Yang, Shu-Wei Yang
  • STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230263887
    Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.
    Type: Application
    Filed: March 10, 2023
    Publication date: August 24, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Manoj K. Sharma, Wendy Benjamin, Sarita Mittal, Ashwin Basarkar, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi, Mohammed Shameem, Soumendu Bhattacharya, William P. Forrest, Jr., Yogita Krishnamachari
  • METHOD FOR DETECTING CYTOMEGALOVIRUS (CMV) AND MEASURING AND QUANTIFYING PENTAMERIC COMPLEX USING AN INDIRECT SANDWICH ELISA
    Publication number: 20230266320
    Abstract: The present invention relates to a method of detecting the presence of Cytomegalovirus and measuring antigenicity through detection and quantification of a pentameric complex by an indirect sandwich ELISA assay which ensures an appropriate concentration of this critical glycoprotein complex is present in the vaccine.
    Type: Application
    Filed: November 20, 2020
    Publication date: August 24, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Cindy J. Pauley, Lawrence William Dick, Jr., Mary Lillian Shank Retzlaff, Matthew C. Troutman, Lynne Ireland Denny, Qiana M. Wilson, Kuo-Chang Yin
  • RIPK1 INHIBITORS AND METHODS OF USE
    Publication number: 20230265094
    Abstract: Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
    Type: Application
    Filed: June 7, 2021
    Publication date: August 24, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jenny Lorena Rico Duque, Phieng Siliphaivanh, Xavier Fradera, Zachary G. Brill, Jing SU
  • HIGH AFFINITY ANTIBODIES TARGETING TAU PHOSPHORYLATED AT SERINE 413
    Publication number: 20230265175
    Abstract: Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.
    Type: Application
    Filed: June 23, 2021
    Publication date: August 24, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jeanne E. Baker, Sophie Parmentier Batteur, Ming-Tang Chen, Alan C. Cheng, Chung-Ming Hsieh, Carl Mieczkowski, Sokreine Suon
  • POLYMERISABLE LIQUID CRYSTAL MATERIAL AND POLYMERISED LIQUID CRYSTAL FILM
    Publication number: 20230265344
    Abstract: The invention relates to a polymerisable LC material comprising at least one di- or multireactive mesogenic compound and at least one compound of formula I, in which the parameter R1, A1, Z1, Z2, n, Sp, P, p1, p2, L1, L2, r1, r2, m and R2 have one of the meanings as given in claim 1. Furthermore, the present invention relates also to a method for the preparation of a polymerisable LC material, a polymer film obtainable from the corresponding polymerisable LC material, to a method of preparation of such polymer film, and to the use of such polymer film and said polymerisable LC material for optical, electro-optical, decorative or security devices.
    Type: Application
    Filed: July 1, 2021
    Publication date: August 24, 2023
    Applicant: MERCK PATENT GMBH
    Inventors: Stephen MULCAHY, Iain GARDINER
  • RADAR-ENABLED COATING CONTAINING METAL EFFECT PIGMENTS ON A SUBSTRATE
    Publication number: 20230265299
    Abstract: The present invention relates to a radar-compatible coating comprising metal-effect pigments on a substrate, to a process for the production of such a coating, and to the use of a substrate coated in this manner, in particular in vehicle construction.
    Type: Application
    Filed: August 31, 2021
    Publication date: August 24, 2023
    Applicant: MERCK PATENT GMBH
    Inventors: Gianfranco PIRONTI, Christoph LANDMANN
  • Composition comprising a semiconducting light emitting nanoparticle
    Patent number: 11732188
    Abstract: The present invention relates to a composition comprising a semiconducting light emitting nanoparticle.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: August 22, 2023
    Assignee: MERCK PATENT GMBH
    Inventors: Yuki Hirayama, Tomohisa Goto, Tadashi Kishimoto, Masayoshi Suzuki, Teruaki Suzuki
  • Carbazole-based Bodipys for organic electroluminescent devices
    Patent number: 11731990
    Abstract: The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: August 22, 2023
    Assignee: Merck Patent GmbH
    Inventors: Amir Parham, Jonas Kroeber, Dominik Joosten, Aurélie Ludemann, Tobias Grossmann
  • Filtration assembly and method for microbiological testing
    Patent number: 11731083
    Abstract: The invention concerns a filtration assembly for microbiological testing and a method of using the filtration assembly for that purpose. The filtration assembly (1) comprises a ring-like membrane support (10) holding a filtration membrane (11), a cylindrical reservoir (20) of which opposite axial ends have openings and one axial opening is removably and fluid-tightly attachable to the membrane support (10) to define a sample volume adjacent to the filtration membrane (11) on one axial side of the membrane support (10); and a lid device (40) removably and fluid tightly attachable to the other axial opening of the reservoir (20) to close the opening. Further, the lid device (40) is removably and fluid tightly attachable to the membrane support (10) so as to seal the one axial side of the membrane support (10) from the environment.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: August 22, 2023
    Assignee: Merck Patent GmbH
    Inventors: Philippe Rivat, Mathieu Arrault, Vincent Schaal
  • Materials for organic electroluminescent devices
    Patent number: 11737352
    Abstract: The present invention relates to compounds of the formulae (1) to (4), which are suitable for use in electronic devices, in particular organic electroluminescent devices, to intermediate compounds for the compounds or formulae (1) to (4) and to electronic devices, which comprise the compounds of formulae (1) to (4).
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: August 22, 2023
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Nils Koenen, Christian Ehrenreich, Philipp Harbach, Lara-Isabel Rodriguez, Rouven Linge, Sebastian Meyer, Aaron Lackner
  • INFLAMMATORY BIOMARKERS FOR PREDICTING RESPONSIVENESS TO FGF-18 COMPOUND
    Publication number: 20230258659
    Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.
    Type: Application
    Filed: September 1, 2022
    Publication date: August 17, 2023
    Applicant: MERCK PATENT GMBH
    Inventors: Christoph H. LADEL, Hans GUEHRING, Anne-Christine BAY-JENSEN, Morten KARSDAL, Per QVIST
  • CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1
    Publication number: 20230257371
    Abstract: The present invention relates to cyclic cyanoenone derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R2, R3, R4 and m are as defined herein. The present invention also relates to pharmaceutical compositions comprising the cyclic cyanoenone derivatives of Formula (I) and to their use in therapy.
    Type: Application
    Filed: July 15, 2021
    Publication date: August 17, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Michael D. Altman, David A. Canditio, Alec H. Christian, Ornella Di Pietro, Min Lu, Umar Faruk Mansoor, Katrina Marie Mennie, Andrew J. Musacchio, Anandan Palani, Michael H. Reutershan, David Matthew Shaw, Ping Lui, Stephen St-Gallay
  • CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS
    Publication number: 20230257348
    Abstract: The present invention is directed to cyclopentapyrrole, furopyrrole and azabicycloheptane compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: August 16, 2021
    Publication date: August 17, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Stephane L. Bogen, Dane James Clausen, Michael T. Rudd, Dong Xiao, Dexi Yang